Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib + Tislelizumab + Chemo in Advanced NSCLC
NCT06969612Phase 1Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of golidocitinib in non-small cell lung cancer (NSCLC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Progression Free Survival at 24 months. Started May 2025; status: recruiting.
02
Drugs
golidocitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06969612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06969612.